Dec 11 The U.S. Food and Drug Administration on
Wednesday approved generic versions of Eli Lilly and Co's
antidepressant Cymbalta, the U.S. drugmaker's
The drug, which has annual sales of about $5 billion, was
expected to lose patent protection this month.
The FDA said it approved cheaper versions of the drug, known
chemically as duloxetine, in a variety of strengths for sale by
several generic drugmakers, including Teva Pharmaceutical
Industries Ltd, Aurobindo Pharma Ltd , Dr.
Reddy's Laboratories Ltd, Lupin Ltd, Sun
Pharmaceutical Industries and Torrent Pharmaceuticals
"Health-care professionals and consumers can be assured that
these FDA-approved generic drugs have met our rigorous
standards," Kathleen Uhl, acting director of the FDA's Office of
Generic Drugs, said in a statement.
Once numerous generic versions of a medicine become
available, the branded drug often loses more than 80 percent of
its sales in the first year.